文献速递骨质疏松与代谢性骨病

英国罗莫佐单抗与特立帕肽治疗骨质疏松的成本效益干预阈值

Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK.
PubMed 文献 · Osteoporos Int · 2024-10-04

该研究采用微观模拟模型,评估英国绝经后极高骨折风险女性中,罗莫佐单抗序贯阿仑膦酸钠或特立帕肽序贯阿仑膦酸钠相比单用阿仑膦酸钠的成本效益。结果显示,在支付意愿为3万英镑时,罗莫佐单抗序贯方案在10年主要骨质疏松性骨折概率18-35%及以上时具成本效益,特立帕肽序贯方案为27-57%。

要点

  • 罗莫佐单抗序贯阿仑膦酸钠在10年MOF概率18-35%及以上时具成本效益,阈值随年龄和部位而异。
  • 特立帕肽序贯阿仑膦酸钠在10年MOF概率27-57%时具成本效益。
  • 70岁及以上罗莫佐单抗序贯方案的成本效益阈值低于NOGG临床阈值,特立帕肽序贯方案则相反。

核心结论

  • 罗莫佐单抗序贯阿仑膦酸钠或特立帕肽序贯阿仑膦酸钠可为骨折极高风险的绝经后女性提供具成本效益的治疗选择。

研究设计与样本

  • 采用具有马尔可夫结构的微观模拟模型,模拟50至90岁近期发生主要骨质疏松性骨折、髋部骨折或脊柱骨折的女性,从5年治疗开始随访至100岁或死亡,分析采用医疗保健视角。
  • 罗莫佐单抗、特立帕肽和阿仑膦酸钠的疗效取自III期随机对照试验,资源使用和单位成本取自文献。

主要发现

  • 基础病例分析显示,在支付意愿为3万英镑时,罗莫佐单抗序贯阿仑膦酸钠在10年MOF概率18-35%及以上时具成本效益,具体阈值取决于年龄和哨兵骨折部位。
  • 特立帕肽序贯阿仑膦酸钠在10年MOF概率27-57%时具成本效益。
  • 结果对药物定价敏感,但对治疗时长、罗莫佐单抗坚持性假设和哨兵骨折部位相对不敏感。
  • 70岁及以上罗莫佐单抗序贯方案的成本效益干预阈值低于NOGG临床阈值;特立帕肽序贯方案的成本效益干预阈值在任何年龄均高于临床阈值,但在近期哨兵骨折基础上合并强临床危险因素时可找到具成本效益的情景。

关键数值与推荐

  • 成本效益干预阈值定义为治疗具成本效益时的10年主要骨质疏松性骨折概率。
  • 罗莫佐单抗序贯阿仑膦酸钠的CEIT为10年MOF概率18-35%及以上,取决于年龄和哨兵骨折部位。
  • 特立帕肽序贯阿仑膦酸钠的CEIT为10年MOF概率27-57%。
  • 支付意愿为3万英镑。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 结果对药物定价敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Sequential romosozumab-to-alendronate or sequential teriparatide-to-alendronate can be a cost-effective treatment option for postmenopausal women at very high risk of fracture. PURPOSE: To estimate the 10-year probability of a major osteoporotic fracture (MOF) at which sequential treatment with romosozumab or teriparatide followed by alendronate, compared with alendronate alone, becomes cost-effective in a UK setting. METHODS: A microsimulation model with a Markov structure was used to simulate fractures, costs, and quality-adjusted life years (QALYs), in women receiving sequential treatment with either romosozumab or teriparatide followed by alendronate, compared with alendronate alone. Patients aged 50 to 90 years with a recent MOF, hip or spine fracture were followed from the start of a 5-year treatment until the age of 100 years or death. The analysis had a healthcare perspective. Efficacy of romosozumab, teriparatide and alendronate was derived from phase III randomised controlled trials. Resource use and unit costs were derived from the literature. Cost-effectiveness intervention threshold (CEIT), defined as the 10-year probability of a major osteoporotic fracture at which treatment becomes cost-effective, was compared with clinically appropriate intervention thresholds for bone-forming treatment in women with very high fracture risk as recommended by the UK National Osteoporosis Guideline Group (NOGG). RESULTS: The base case analysis showed that sequential romosozumab-to-alendronate treatment was cost-effective from a 10-year MOF probability of 18-35% and above depending on age and site of sentinel fracture at a willingness to pay (WTP) of £30,000. For teriparatide-to-alendronate, treatment was cost-effective at a 10-year MOF probability of 27-57%. The results were sensitive to pricing of the drugs but relatively insensitive to treatment duration, romosozumab persistence assumptions, and site of sentinel fracture. The CEITs for romosozumab-to-alendronate treatment were lower than the clinical thresholds from the age of 70 years meaning that treatment could be considered both cost-effective and aligned with the NOGG treatment guidelines. By contrast, for teriparatide-to-alendronate the CEITs were higher than the clinical thresholds irrespective of age. However, cost-effective scenarios were found in the presence of strong clinical risk factors in addition to a recent sentinel fracture. CONCLUSION: The results of this study indicate that sequential romosozumab-to-alendronate or teriparatide-to-alendronate treatment can be a cost-effective treatment option for postmenopausal women at very high risk of fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Borgström F, Lorentzon M, Johansson H, et al. Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. Osteoporos Int. 2024. PMID: 39365433. doi:10.1007/s00198-024-07251-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。